Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Cell death or cancer growth: a question of cohesion

No. 54 | 19/11/2019 | by Koh

Activation of CD95, a receptor found on all cancer cells, triggers programmed cell death – or does the opposite, namely stimulates cancer cell growth. Scientists from the German Cancer Research Center (DKFZ) have now shown that the impact of CD95 activation depends on whether there are isolated cancer cells or three-dimensional structures. Individual cells are programmed to die following CD95 activation. In contrast, CD95 activation stimulates growth in clusters of cancer cells, for example in solid tumors. This finding points to new ways of specifically transforming growth-stimulating signals into cell death signals for the cancer cells.

CD95-activation in isolated cancer cells leads to apoptosis. In contrast, it is a growth stimulus for cancer cells growing in three-dimensional structures.
© G. Gülcüler/DKFZ

The receptor protein CD95 is exposed on the surface of all cancer cells like small antennae. Activation of the receptor by the CD95 ligand (CD95L) triggers apoptosis in the cancer cell – or the exact opposite: "We studied various types of cancer tissue and found that CD95 activation usually stimulates tumor growth under natural conditions," remarked Ana Martin-Villalba, who has been conducting research at DKFZ on the role of CD95 for many years now. She was the first to describe the cancer-promoting effect of CD95 in glioblastomas (malignant brain tumors).

Researchers are investing considerable effort into examining how medicine could harness the other side of CD95 and cause cancer cells to die in a targeted way. To do so, Martin-Villalba and her team attempted to understand which factors decide whether CD95 activation leads to cell death or cell growth.

The team from DKFZ collaborated with Motomu Tanaka from the University of Heidelberg, jointly developing artificial cell membranes into which they could insert any amount of the CD95 ligand. Using this method, they discovered that a particular distance between the individual ligand molecules was necessary to achieve ideal activation of CD95 – and to actually induce cell death in cells isolated from biopsies of pancreatic cancer or glioblastomas grown in a petri dish.

The researchers then assumed that they had found the perfect way to cause tumor cells in the body to die and extended their experiments to brain tumors in mice. They gave the animals latex beads with the ideal surface density of CD95 ligands. However, instead of observing a reduction in the tumor mass, as expected, the opposite occurred: tumor growth was accelerated.

In order to clarify the apparent discrepancy between cell culture and animal experiments, the researchers experimented with "tumorspheres," tiny tumors grown in culture. CD95 activation via the artificial cell membrane stimulated growth in these cell spheroids, which behaved like natural tumor tissue.

"The impact of CD95 activation – cell death or growth – appears to depend primarily on whether there are isolated cancer cells, as grown in culture, or cells in three-dimensional structures," Gülce Gülcüler from Martin-Villalbas' team explained. Individual cells are programmed to die following CD95 activation. In natural conditions, however, namely in a tissue structure, CD95 activation stimulates growth. In Gülcüler's experiments, even contact to a single neighboring cell was enough to protect tumor cells from CD95-induced cell death.

"The result will enable us to develop new strategies to transform the growth-stimulating signals of CD95 into cell death signals for the cancer cells. This could help us stop tumor cells becoming resistant to treatment," study director Martin-Villalba added.

A clinical phase II study conducted several years ago already showed that, when combined with radiotherapy, blocking the CD95 signal could lead to better survival rates in patients with advanced glioblastomas. The study used a substance that Ana Martin-Villalba played a key role in developing. "Our current findings provide an explanation for the first time of why blocking CD95 does actually slow down cell death," Martin-Villalba explained.

Gülce S. Gülcüler Balta, Cornelia Monzel, Susanne Kleber, Joel Beaudouin, Emre Balta, Thomas Kaindl, Si Chen, Liang Gao, Meinolf Thiemann, Christian R. Wirtz, Yvonne Samstag, Motomu Tanaka and Ana Martin-Villalba: 3D cellular architecture modulates tyrosine kinase activity thereby switching CD95 mediated apoptosis to survival.
Cell Reports 2019, DOI: 10.1016/j.celrep.2019.10.054

Why animal experiments are vital in cancer research

Death signals or growth stimulators – up to now, scientists did not know why CD95 activation in cancer cells can have such different outcomes. As a result, they were unable to conduct further targeted research into this signaling system – so promising for cancer treatment – to benefit patients.

The different outcomes of the experiments on cancer cells grown in culture and on brain tumors in mice allowed the researchers to find the explanation for the first time. Using tumorspheres, the researchers were subsequently able to confirm the effect of cell contact in an experimental setting and rule out other influencing factors such as the immune system.

This finding will enable the therapeutic potential of blocking CD95 to be harnessed in a much more targeted way.

A picture is available for download:
https://www.dkfz.de/de/presse/pressemitteilungen/2019/bilder/CD95-activation.jpg 

Picture Caption: CD95-activation in isolated cancer cells leads to apoptosis. In contrast, it is a growth stimulus for cancer cells growing in three-dimensional structures.

Note on use of images related to press releases
Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: "Source: G. Gülcüler/DKFZ".
Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ's Press Office (phone: ++49-(0)6221 42 2854, E-mail: presse@dkfz.de). Any commercial use is prohibited.

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS